KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Equity Average (2016 - 2025)

Historic Equity Average for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to $80.2 million.

  • Arbutus Biopharma's Equity Average fell 3007.23% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.2 million, marking a year-over-year decrease of 3007.23%. This contributed to the annual value of $101.7 million for FY2024, which is 1625.81% down from last year.
  • Arbutus Biopharma's Equity Average amounted to $80.2 million in Q3 2025, which was down 3007.23% from $81.1 million recorded in Q2 2025.
  • Arbutus Biopharma's Equity Average's 5-year high stood at $167.6 million during Q1 2022, with a 5-year trough of $80.2 million in Q3 2025.
  • Its 5-year average for Equity Average is $121.7 million, with a median of $115.5 million in 2021.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 5514.15% in 2022, then tumbled by 3161.57% in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Equity Average stood at $149.8 million in 2021, then decreased by 5.74% to $141.2 million in 2022, then fell by 20.19% to $112.7 million in 2023, then decreased by 9.36% to $102.1 million in 2024, then dropped by 21.48% to $80.2 million in 2025.
  • Its last three reported values are $80.2 million in Q3 2025, $81.1 million for Q2 2025, and $88.3 million during Q1 2025.